Morningstar

Cellectis SA CMVLF

Stock OTCM

$0.97 −0.00 (0.46%)

View Full Chart

As of Oct 22, 2026, 5:23:48 PM Delayed Price Closed

Trading Information

Previous Close Price: $0.97
Day Range: $0.97–1.02
52-Week Range: $0.97–5.04
Bid/Ask: $0.93 / $1.25
Shares Outstanding: 100.73M
Market Cap: $97.12M
Volume/Avg: 13,100 / 4,882

Key Statistics

Price/Earnings (Normalized): —
Price/Sales: 1.71
Dividend Yield (Trailing): 0.00%
Dividend Yield (Forward): 0.00%
Dividend Payment Schedule: —
Total Yield: —

Company Profile

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Sector: Healthcare
Industry: Biotechnology
Stock Style Box: Small Core
Total Number of Employees: 229
Website: https://www.cellectis.com

Biotechnology Industry Comparables

Screen With Investor

1-Day Chart	Name	Price	Morningstar Rating for Stocks	Capital Allocation	Economic Moat	Market Cap
	Vertex Pharmaceuticals Inc VRTX			LOCK\|tCfb>q	LOCK\|Dnt!<	$133B
	Regeneron Pharmaceuticals Inc REGN			LOCK\|QBj?N%M	LOCK\|ChH?	$83B
	Moderna Inc MRNA			LOCK\|MDnPN>^	LOCK\|Z%>	$80B
	argenx SE ADR ARGX			LOCK\|W#Qmhq	LOCK\|?<W	$55B
	BeOne Medicines Ltd ADR ONC			LOCK\|W!RV>vN	LOCK\|?SP	$45B
	Alnylam Pharmaceuticals Inc ALNY			LOCK\|&m<BH!	LOCK\|B#%r	$30B
	Royalty Pharma PLC Class A RPRX			LOCK\|yY%K$wq	LOCK\|#mFTV	$28B
	Incyte Corp INCY			LOCK\|>?JT$V	LOCK\|>%	$23B
	BioNTech SE ADR BNTX			LOCK\|hXb>&S	LOCK\|!Z	$22B
	Jazz Pharmaceuticals PLC JAZZ			LOCK\|%$n!lm	LOCK\|D&g	$14B

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.